Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma

Kevin R. Kelly, MD PhD, David S. Siegel, MD PhD, Asher A. Chanan-Khan, MD, George Somlo, MD, Leonard T. Heffner, MD, Sundar Jagannath, MD, Todd Zimmerman, MD, Nikhil C Munshi, MD, Sumit Madan, MD, Ann Mohrbacher, MD, Sagar Lonial, MD FACP, Farima Barmaki-Rad, MD, Markus Rühle, MD, Eva Herrmann, MSc, Andrea Wartenberg-Demand, MD, Thomas Haeder, PhD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 4486.

https://doi.org/10.1182/blood.V128.22.4486.4486

Published: 2016

Journal Articles

Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib

Kevin R. Kelly, MD, Asher Chanan-Khan, MD, Leonard T Heffner, MD, George Somlo, MD, David S. Siegel, MD PhD, Todd Zimmerman, MD, Anand Karnad, MD, Nikhil C. Munshi, MD, Sundar Jagannath, MD, Allen L. Greenberg, MD, Sagar Lonial, MD, Vivek Roy, MD, Sikander Ailawadhi, MD, Farima Barmaki-Rad, MD, Shailesh Chavan, MD, Pankaj Patel, PhD, Andrea Wartenberg-Demand, MD, Thomas Haeder, PhD, Kenneth C Anderson, MD

Blood (2014) 124 (21): 4736.

https://doi.org/10.1182/blood.V124.21.4736.4736

Published: 2014

Journal Articles

Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients

Kevin R. Kelly, MD, PhD, Asher Chanan-Khan, MD, George Somlo, MD, Leonard T Heffner, MD, David S Siegel, MD, PhD., Todd M Zimmerman, MD, Sundar Jagannath, MD, Nikhil C. Munshi, MD, Sagar Lonial, M.D., Vivek Roy, M.D., Markus Ruehle, MD, Shailesh Chavan, MD, Pankaj Patel, PhD, Markus Rothenburger, MD, Andrea Wartenberg-Demand, MD, Thomas Haeder, PhD, Kenneth C. Anderson

Blood (2013) 122 (21): 758.

https://doi.org/10.1182/blood.V122.21.758.758

Published: 2013

Journal Articles

BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity

Leonard T Heffner, MD, Sundar Jagannath, MD, Todd M Zimmerman, MD, Kelvin P Lee, MD, Jacalyn Rosenblatt, MD, Sagar Lonial, MD, Robert J. Lutz, PhD, Niklas Czeloth, PhD, Frank Osterroth, PhD, Markus Ruehle, MD, Michelle A. Beelitz, Andrea Wartenberg-Demand, MD, Thomas Haeder, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2012) 120 (21): 4042.

https://doi.org/10.1182/blood.V120.21.4042.4042

Published: 2012

Journal Articles

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Sundar Jagannath, MD, Asher Chanan-Khan, MD, Leonard T. Heffner, MD, David Avigan, MD, Todd M. Zimmerman, MD, Sagar Lonial, MD, Robert J. Lutz, PhD, Andre Engling, PhD, Christoph Uherek, PhD, Frank Osterroth, PhD, Markus Ruehle, MD, Michelle A. Beelitz, Gabriele Niemann, PhD, Andrea Wartenberg-Demand, MD, Thomas Haeder, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2011) 118 (21): 305.

https://doi.org/10.1182/blood.V118.21.305.305

Published: 2011

Journal Articles

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Sundar Jagannath, MD, Asher A. Chanan-Khan, MD, Leonard T Heffner, MD, David Avigan, MD, Robert J Lutz, PhD, Christoph Uherek, PhD, Frank Osterroth, PhD, Markus Ruehle, MD, Thomas Haeder, PhD, Gabriele Niemann, PhD, Andrea Wartenberg-Demand, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson

Blood (2010) 116 (21): 3060.

https://doi.org/10.1182/blood.V116.21.3060.3060

Published: 2010

NARROW

Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma

Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib

Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients

BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma

Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib

Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients

BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only